NCT00144872 - LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2004

Primary Completion Date

April 22, 2006

Study Completion Date

April 22, 2006

Conditions

Seizure, Absence

Interventions

DRUG

Lamotrigine

Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.

Trial Locations (23)

14222

GSK Investigational Site, Buffalo

14642

GSK Investigational Site, Rochester

27607

GSK Investigational Site, Raleigh

27834

GSK Investigational Site, Greenville

30342

GSK Investigational Site, Atlanta

32308

GSK Investigational Site, Tallahassee

32405

GSK Investigational Site, Panama City

32901

GSK Investigational Site, Melbourne

33470

GSK Investigational Site, Loxahatchee Groves

37212

GSK Investigational Site, Nashville

38138

GSK Investigational Site, Germantown

40202

GSK Investigational Site, Louisville

53215

GSK Investigational Site, Milwaukee

53226

GSK Investigational Site, Milwaukee

53792

GSK Investigational Site, Madison

65804

GSK Investigational Site, Springfield

76104

GSK Investigational Site, Fort Worth

95128

GSK Investigational Site, San Jose

97239

GSK Investigational Site, Portland

98105

GSK Investigational Site, Seattle

33607-6350

GSK Investigational Site, Tampa

07103

GSK Investigational Site, Newark

27599-7600

GSK Investigational Site, Chapel Hill